If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

In early March 2026, Pfizer reported past Phase 2 trial results showing its investigational trispecific antibody tilrekimig significantly improved eczema severity versus placebo in adults with ...

Pfizer (NYSE:PFE) has agreed to acquire Metsera (NASDAQ:MTSR) in a deal worth $47.50 per share in cash, valuing the company at $4.9 billion upfront, with the potential for shareholders to receive up ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...